Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

Related Issuers

PRICED: OCI 5NC2 E400m 3.625% @100; $400m 4.625% @100

HYC US Market: Deal Flow - GeneralHYC European Market: Deal Flow - General

OCI NV (OCINV) approx US$870m (up from US$860m) equivalent (US$/EUR) 144A/Reg S sr sec notes 2-part due 2025 (5y). Ba3/BB/(expect BB) (negative/negative/--). Via Barc (B&D) /BofA/HSBC joint glocos/BNPP/Citi/CA/GS/JPM/Rabo/SocGen joint books. No reg rights. List ISE. NY law. Settles 10/09 (T+7).

- EUR400m (up from EUR350m) due 10/15/25 (5y). NC2 (MWC B+50bp), then at 101.813, 100.906, 100. Equity claw: 2y 40% at 103.625. Special call: 10% per year the 1st 2 years at 103. Reg S ISIN: XS2241400295. IPT: 3.75%-4.00%. Px talk: 3.75% area. Launched: EUR400m at 3.625%. Priced: 3.625% at 100. +434.7bp vs OBL 0% 10/10/25.

- US$400m (down from US$450m) due 10/15/25 (5y). NC2 (MWC T+50bp), then at 102.313, 101.156, 100. Equity claw: 2y 40% at 104.625. Special call: 10% per year the 1st 2 years at 103. 144A CUSIP: 67091GAE3. IPT: 5.00% area. Px talk: 4.50%-4.75%. Launched: US$400m at 4.625%. Priced: 4.625% at 100. +436.5bp vs UST 3% 10/31/25.

Did investor call at 2:30pm UKT/9:30am NYT 09/29. Books closed: EUR at 11:30am UKT today (09/30); US$ at 5pm yesterday (09/29). Orders were to be reconfirmed by 9:30am NYT, 2:30pm UKT. UOP: along with an approx $300m draw on its revolver to repay its US$650m 6.625% sr sec notes due 04/15/23 (callable at 103.3125) and EUR400m 5.00% sr sec notes due 04/15/23 (callable at 102.50). The Sawiris family are the principal shareholders with 54.37% ownership stake. Biz: is a leading global producer and distributor of nitrogen products and methanol with global manufacturing footprint. HQ: Amsterdam, Netherlands.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.